Provided is an applicator for the dispensing of a powder such as a pharmaceutical powder, on a target location. Also, provided are methods of applying a powder on a surface using the applicator.

A delivery device for and a method of delivering gases to the nasal airway, in particular therapeutic gases and gases in combination with active substances, either as powders or liquids, for enhanced uptake of the active substances.

A dispenser device for fluid or powder, including an air expeller (20) and a reservoir (30). The reservoir (30) has an air inlet (31) connected to the air expeller (20) and a composition outlet (32) connected to a dispenser opening (10), and is removably mounted on the air expeller. After actuation, the empty reservoir can be removed from the air expeller and replaced with a new reservoir. The air inlet (31) is closed by a first closure element (40) and the composition outlet (32) is closed by a second closure element (50). A mechanical opening system (61, 62) co-operates with the first and second closure elements to expel each closure element from the closed position. The mechanical opening system has a first rod (61) secured to the air expeller (20), and a second rod (62) secured to the dispenser head (1), co-operating with a closure element during actuation.

Containment units, dry powder inhalers, delivery systems, and methods for the same are disclosed. Exemplary devices are configured to have inlets and outlets which are formed with the containment walls of a containment unit. Air jets formed by the configuration of inlet(s) and outlet(s) inside the containment unit create significant turbulence and deaggregate the powder. Delivery system components downstream of the containment unit may integrate the exiting aerosol plume with a low flow nasal cannula air stream for delivery to a subject.

Containment units, dry powder inhalers, delivery systems, and methods for the same are disclosed. Exemplary devices are configured to have inlets and outlets which are formed with the containment walls of a containment unit. Air jets formed by the configuration of inlet(s) and outlet(s) inside the containment unit create significant turbulence and deaggregate the powder. Delivery system components downstream of the containment unit may integrate the exiting aerosol plume with a low flow nasal cannula air stream for delivery to a subject.

A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.

A dry powder inhaler includes a powder storage element configured to hold a powdered medicament and an inlet channel receives, powdered medicament from the powder storage element that is entrained in an airflow. The inlet channel has a first diameter and defines an opening. The inhaler includes a dispersion chamber that receives the airflow and the powdered medicament from the opening. The dispersion chamber has a second diameter. The inhaler includes an actuator housed within the dispersion chamber. The actuator oscillates within the dispersion chamber when exposed to the airflow to deaggregate the powdered medicament entrained by the airflow passing through the dispersion chamber. A ratio between the first diameter and the second diameter is between about 0.40 and 0.60 such that an audible sound is produced as the actuator oscillates. The inhaler includes an outlet channel through which the airflow and powdered medicament exit the inhaler.

A dry powder inhaler includes a powder storage element configured to hold a powdered medicament and an inlet channel receives, powdered medicament from the powder storage element that is entrained in an airflow. The inlet channel has a first diameter and defines an opening. The inhaler includes a dispersion chamber that receives the airflow and the powdered medicament from the opening. The dispersion chamber has a second diameter. The inhaler includes an actuator housed within the dispersion chamber. The actuator oscillates within the dispersion chamber when exposed to the airflow to deaggregate the powdered medicament entrained by the airflow passing through the dispersion chamber. A ratio between the first diameter and the second diameter is between about 0.40 and 0.60 such that an audible sound is produced as the actuator oscillates. The inhaler includes an outlet channel through which the airflow and powdered medicament exit the inhaler.

The present invention provides for the integration of drug dispersion methods into a drug or medicine delivery system. The drug dispersion methods used include shear (e.g., air across a drug, with or without a gas assist), capillary flow or a venturi effect, mechanical means such as spinning, vibration, or impaction, and turbulence (e.g., using mesh screens, or restrictions in the air path). These methods of drug dispersion allow for all of the drug in the system to be released, allowing control of the dosage size. These methods also provide for drug metering, fluidization, entrainment, deaggragation and deagglomeration. The present invention also provides for the integration of a drug sealing system into the device. The drug sealing system provides a way of blocking the migration of drug from one area of the package to another. The drug seal system can also provide a method of tightly containing the drug until the package is opened, of directing airflow through the package and of managing and containing the drug during the package/device manufacturing process.

Exemplary dry powder inhaler devices may include a housing body having a medicine capsule recess therein, a pair of air inlets each fluidically connecting to the recess, and an outlet body coupled to the housing body. Each inlet may have a width no greater than 1.17 mm. The outlet body may have a channel fluidically connecting the recess to an opening and configured to allow a user to draw air through the opening, thereby allowing an airstream to be drawn through the air inlets, into the housing body recess where it causes the capsule to spin and eject its contents into the airstream, and through the outlet body channel and opening to deliver the substance into the user's lungs. Dry powder respirable drug blend formulations, methods of manufacturing the formulations and drug/device combinations are also provided.